INEX Innovate is Asia's leading molecular diagnostics company for women, dedicated to delivering precision healthcare. They specialize in developing and commercializing new technologies to address unmet needs in women's and fetal health. With a commitment to innovation, INEX Innovate constantly innovates to address valuable clinical unmet needs through diagnostic test offerings.

They have developed a broad range of intellectual property and are focused on improving women's health through innovative diagnostics. Their product portfolio includes groundbreaking solutions like epiHERA™, a Minimally Invasive Early Endometrial Cancer Detection Test, CORO® Real-Time RT-PCR SARS-CoV-2 kit, OvaCis® for the accurate discrimination of benign and malignant epithelial ovarian cysts, epiDX® for the early diagnosis of breast cancer, LEXI® for the isolation of fetal cells in maternal blood, and XENA®, an early detection blood test for ovarian cancer. INEX Innovate's team of experts is dedicated to developing diagnostics platforms based on hard science.

They strive to provide value to the most important stakeholder – the patient. As a research-driven company, INEX Innovate is committed to delivering innovative solutions to address women's health challenges and ensure equity and access to their products. They actively seek partnerships to support research programs, diversify their portfolio, and accelerate the development of innovative diagnostic tools.

Together, they aim to improve the lives of women around the world. Headquartered in Singapore, INEX Innovate has a global footprint with operations in the USA, China, the United Kingdom, Hong Kong, Indonesia, India, Bangladesh, Myanmar, Malaysia, and Thailand. They have a proven track record of successful partnerships, ongoing projects, and a robust intellectual property portfolio.

With a focus on scientific discoveries and clinical practice, INEX Innovate is shaking up the diagnostics status quo to make a difference in women's healthcare